Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eduard Roussel

Showing results (11-20 of 104) with videos related to

Pageof 11
Sort By:
Minerva Urology and Nephrology|January 20, 2025
YAU renal cancer spotlight: how should cost-effectiveness affect decision-making regarding adjuvant pembrolizumab for clear cell renal cell carcinoma?Selcuk Erdem, Laura Marandino, Eduard Roussel, et al.
Minerva Urology and Nephrology|December 21, 2023
"Sutureless success:" can new devices make renorrhaphy after partial nephrectomy obsolete?Eduard Roussel, Daniele Amparore, Riccardo Bertolo, et al.
Minerva Urology and Nephrology|September 8, 2021
Renal tumors ablationMichele Marchioni, Daniele Amparore, Alexandre Ingels, et al.
European Urology Oncology|November 19, 2023
Re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2023;6:266-274Eduard Roussel, Riccardo Bertolo, Chiara Ciccarese, et al.
Minerva Urology and Nephrology|August 2, 2023
Renal cell carcinoma with non-clear cell histologies: all the same peas in one pod?Eduard Roussel, Daniele Amparore, Riccardo Bertolo, et al.
Minerva Urology and Nephrology|December 21, 2023
The World Health Organization 2022 Classification of renal tumors: key updates for urologistsAnna Caliò, Daniele Amparore, Eduard Roussel, et al.
European Urology|February 26, 2022
Novel Imaging Methods for Renal Mass Characterization: A Collaborative ReviewEduard Roussel, Umberto Capitanio, Alexander Kutikov, et al.
Urologic Oncology|January 24, 2021
C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumabEduard Roussel, Lisa Kinget, Annelies Verbiest, et al.
Scandinavian Journal of Urology|September 14, 2020
Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinomaEduard Roussel, Annelies Verbiest, Uros Milenkovic, et al.
Urologic Oncology|September 9, 2020
Pushing the limits of metastasis-directed treatment in metastatic renal cell carcinoma in the era of targeted therapySerge Holz, Lorenzo Tosco, Murat Akand, et al.
Pageof 11

Showing results (11-20 of 104) with videos related to

Sort By:
Pageof 11
Minerva Urology and Nephrology|January 20, 2025
YAU renal cancer spotlight: how should cost-effectiveness affect decision-making regarding adjuvant pembrolizumab for clear cell renal cell carcinoma?Selcuk Erdem, Laura Marandino, Eduard Roussel, et al.
Minerva Urology and Nephrology|December 21, 2023
"Sutureless success:" can new devices make renorrhaphy after partial nephrectomy obsolete?Eduard Roussel, Daniele Amparore, Riccardo Bertolo, et al.
Minerva Urology and Nephrology|September 8, 2021
Renal tumors ablationMichele Marchioni, Daniele Amparore, Alexandre Ingels, et al.
European Urology Oncology|November 19, 2023
Re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2023;6:266-274Eduard Roussel, Riccardo Bertolo, Chiara Ciccarese, et al.
Minerva Urology and Nephrology|August 2, 2023
Renal cell carcinoma with non-clear cell histologies: all the same peas in one pod?Eduard Roussel, Daniele Amparore, Riccardo Bertolo, et al.
Minerva Urology and Nephrology|December 21, 2023
The World Health Organization 2022 Classification of renal tumors: key updates for urologistsAnna Caliò, Daniele Amparore, Eduard Roussel, et al.
European Urology|February 26, 2022
Novel Imaging Methods for Renal Mass Characterization: A Collaborative ReviewEduard Roussel, Umberto Capitanio, Alexander Kutikov, et al.
Urologic Oncology|January 24, 2021
C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumabEduard Roussel, Lisa Kinget, Annelies Verbiest, et al.
Scandinavian Journal of Urology|September 14, 2020
Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinomaEduard Roussel, Annelies Verbiest, Uros Milenkovic, et al.
Urologic Oncology|September 9, 2020
Pushing the limits of metastasis-directed treatment in metastatic renal cell carcinoma in the era of targeted therapySerge Holz, Lorenzo Tosco, Murat Akand, et al.
Pageof 11